STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset
methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Cook Children's Medical Center Indiana University National Jewish Health St. Louis Children's Hospital University of Michigan University of Texas Southwestern Medical Center University of Washington